European Respiratory Journal · 1994 · 25 citations · 4 references
MedicineOncologySurgeryImmunotherapyOncologic SurgerySurgical OncologyCancer ImmunotherapyImmunotherapy For Solid TumorsImmunotherapy For Thoracic MalignanciesIntravenous Access DevicesCancer Therapy ImplantsImmunotherapy For Pleural MalignanciesMalignant Pleural EffusionMalignant Pleural Mesothelioma ImmunotherapyPort Access Care
We describe our experience using an implantable Port-A-Cath access system for intrapleural administration of gamma-interferon (gamma-IFN) in malignant mesothelioma patients. Twenty nine patients, with histologically proven malignant mesotheliomas were included in this study. To avoid complications the device was implanted in a subcutaneous pocket, and the catheter was connected via a tunnel. Also, a suction drain was installed in the pocket after placement. This procedure greatly reduced the high infection rate (64%) encountered with conventional open chest tubes. Patients' tolerance was excellent and maintenance minimal. In our opinion, the Port-A-Cath system is the most suitable device for intra-cavitary long-term therapy of malignant pleural effusions.
4
Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
C Boutin, J. R. Viallat, Nico van Zandwijk et al. · Cancer · 1991 · 129 citations · Full text
Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma
Maurie Markman, Stephen Cleary, C E Pfeifle et al. · Cancer · 1986 · 83 citations
Medicine, Oncology, Pharmacology +16
Totally implantable system for peritoneal access.
C E Pfeifle, Stephen B. Howell, Maurie Markman et al. · Journal of Clinical Oncology · 1984 · 75 citations